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Abstract  
Background 
Mutations in the Abnormal Spindle Microcephaly related gene (ASPM) are the 
commonest cause of autosomal recessive primary microcephaly (MCPH) a disorder 
characterised by a small brain and associated mental retardation. ASPM encodes a 
mitotic spindle pole associated protein. It is suggested that the MCPH phenotype 
arises from proliferation defects in neural progenitor cells (NPC).  
Results 
We show that ASPM is a microtubule minus end-associated protein that is recruited in 
a microtubule-dependent manner to the pericentriolar matrix (PCM) at the spindle 
poles during mitosis. ASPM siRNA reduces ASPM protein at the spindle poles in 
cultured U2OS cells and severely perturbs a number of aspects of mitosis, including 
the orientation of the mitotic spindle, the main determinant of developmental 
asymmetrical cell division. The majority of ASPM depleted mitotic cells fail to 
complete cytokinesis. In MCPH patient fibroblasts we show that a pathogenic ASPM 
splice site mutation results in the expression of a novel variant protein lacking a 
tripeptide motif, a minimal alteration that correlates with a dramatic decrease in 
ASPM spindle pole localisation. Moreover, expression of dominant-negative ASPM 
C-terminal fragments cause severe spindle assembly defects and cytokinesis failure in 
cultured cells.  
Conclusions 
These observations indicate that ASPM participates in spindle organisation, spindle 
positioning and cytokinesis in all dividing cells and that the extreme C-terminus of the 
protein is required for ASPM localisation and function. Our data supports the 
hypothesis that the MCPH phenotype caused by ASPM mutation is a consequence of 
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mitotic aberrations during neurogenesis. We propose the effects of ASPM mutation 
are tolerated in somatic cells but have profound consequences for the symmetrical 
division of NPCs, due to the unusual morphology of these cells. This antagonises the 
early expansion of the progenitor pool that underpins cortical neurogenesis, causing 
the MCPH phenotype. 
Background  
During neurogenesis the majority of neurons and glia in the mammalian neocortex 
arise from the division of NPC in the neuroepithelial lining of the central cavities of 
the brain (1). Primary NPC have a specific pattern of mitotic activity. Initially each 
symmetrical division increases precursor cell number by generating two progenitor 
cells per division. Subsequent asymmetric neurogenic divisions produce one neuron 
and regenerate one progenitor cell (2). In the developing mammalian cortex the 
division fate of a cell appears dependent upon the orientation of the mitotic spindle 
and hence the position of the cleavage furrow with respect to the apical surface of the 
neuroepithelium (3). As a result of the inheritance of cell lineage determinants located 
at the apical cell membrane, cleavage parallel to the apical surface results in 
neurogenic division where the apical contents are inherited by one daughter cell and 
the basal contents by the other, whereas perpendicular cleavage produces two 
daughter progenitor cells. The mechanisms regulating spindle orientation and 
cleavage furrow positioning in the mammalian neuroepithelium are not well 
understood. 
Autosomal recessive primary microcephaly (MCPH) is a rare Mendelian 
disorder characterized by a congenital deficiency of foetal brain growth, particularly 
affecting the neocortex. This results in the formation of a small but structurally 
normal brain and associated mental retardation but no other neurological defects (4,5).  
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The concept that MCPH is a primary disorder of neurogenic mitosis, the result of 
which is a reduction of cell number in the developing human brain, is an attractive 
one.  
Mutations that cause the condition have been found in five genes: 
microcephalin (MCPH1), which functions in the DNA damage response pathway; and 
abnormal spindle-like microcephaly associated gene (ASPM), CDK5 regulatory 
subunit-associated protein 2 (CDK5RAP2), centromeric protein J (CENPJ) and 
SCL/TAL1-interupting locus (STIL) which are all associated with aspects of 
centrosome function (5-13). The most common cause of MCPH is mutation of the 
ASPM gene (5,14,15) at the MCPH5 locus on chromosome 1q31 (16,17). All known 
pathogenic mutations produce a single clinical phenotype (5,15) even though they 
include nonsense, frameshift, translocation and splice site mutations located 
throughout the 28 exon ASPM gene (5,8,15,18-23). It was originally assumed that 
mutations result in either protein truncation or mRNA degradation via the nonsense 
mediated decay (NMD) pathway (24).  
The human ASPM gene encodes a protein composed of 3477 amino acids (5) 
that is predicted to contain an amino terminal microtubule binding domain (25); two 
highly conserved N-terminal short ASNP (ASPM N-proximal) repeats (8); two 
calponin homology domains; up to 81 calmodulin binding isoleucine-glutamine (IQ) 
motifs (5,8,26,27); an armadillo-like sequence and a carboxyl terminal region of 
unknown function (5,15). Figure 1A summarizes the domain structure of the ASPM 
protein. ASPM is expressed in all proliferating tissues and is upregulated in many 
cancers (8). 
 Human ASPM is the orthologue of the Drosophila abnormal spindle gene 
(asp). Asp is involved in spindle microtubule organisation in mitosis and meiosis (25, 
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28-31) and in cytokinesis (32,33). In dividing Drosophila neuroblasts asp mutations 
cause metaphase arrest, resulting in reduced CNS development (29). siRNA depletion 
of asp produces a severe loss of microtubule focus at spindle poles (34). In mice, 
elimination of Aspm results in a reduction in neural stem cell proliferation and 
increases the likelihood that NPCs will undergo asymmetric cell division, implying a 
reduction in the total number of progenitor cells formed during brain development 
(35). Inhibition of human ASPM expression by siRNA-mediated knockdown inhibits 
tumour cell proliferation (36). Although it has been hypothesized that ASPM is 
required for cell division in the developing human brain, direct evidence in support of 
this has been lacking. 
In the present study we investigate the role of ASPM in human cell division 
and extend the characterization of the mitotic distribution of human ASPM. We show 
that ASPM knockdown in U2OS osteosarcoma cells by siRNA alters the positioning 
of the mitotic spindle from parallel to the substrate to perpendicular to the substrate, 
effectively altering the division symmetry from symmetrical to asymmetrical. ASPM 
siRNA-mediated depletion also induced cytokinesis failure and apoptosis. Moreover 
we show that a pathogenic mutation identified in an MCPH patient, and located in the 
3’region of the ASPM gene instigates the activation of an upstream in frame cryptic 
splice donor site, resulting in the splicing out of nine nucleotides (nt) from the ASPM 
sequence. The resultant protein exhibits decreased efficiency in localization to spindle 
poles, suggesting the presence of the C-terminal domain is of critical importance for 
ASPM function. Supporting this, we find that ASPM C-terminal fragments expressed 
in transfected cells induce dominant-negative defects on spindle organisation and 
cytokinesis. This study provides further evidence for the function of ASPM in the 
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division cycle of mammalian cells. We discuss these findings in relation to cerebral 
cortex neurogenesis and microcephaly. 
Results and Discussion 
 
ASPM is a nuclear protein that relocates to the spindle pole matrix and central 
spindle MT minus ends during mitosis 
To determine the intracellular distribution of human ASPM, rabbit polyclonal 
antibodies were raised against ASPM-specific peptide sequences (Figure 1A) and 
used to screen a panel of cell lines by immunofluorescence. Two antibodies against N-
terminal peptides (216-1 and 217-2) and one antibody against a C-terminal peptide 
(279-3) produced virtually identical staining patterns (see Additional file 1, 2, 3) in a 
variety of human cell types including HeLa, primary human dermal fibroblasts 
(HDF), U2OS osteosarcoma cells, SH-SY5Y neuroblastoma cells and in COS-7 
African green monkey kidney cells. Pre-incubation with the associated ASPM peptide 
negated the ASPM signal (data not shown). As previously published (37), we found 
ASPM expression to be predominantly concentrated in the nucleus during interphase 
(Figure 1B), however we did not find evidence of centrosomal distribution. Consistent 
with this finding, the ASPM sequence contains a number of potential nuclear 
localization sequences (Figure 1A). No specific association with microtubules or 
microtubule-organizing centres was observed prior to nuclear envelope breakdown. In 
agreement with previous reports, ASPM immunoreactivity shifted away from 
condensing DNA and onto spindle structures immediately after nuclear envelope 
breakdown, and from prometaphase to anaphase ASPM was seen almost exclusively 
associated with the mitotic spindle (Figure 1C) (8,37,38). We localized mitotic ASPM 
immunoreactivity to pole-proximal regions of spindle microtubules, where it formed a 
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ring around the spindle poles. This ring enclosed but did not extensively overlap with 
γ-tubulin immunoreactivity (Figure 1D), though it co-localised with Dynactin 1 
(DCTN1) immunoreactivity in the pericentriolar matrix (PCM, data not shown). In 
anaphase cells the mitotic spindle has flattened and ASPM maintains its spindle pole 
localisation, was observed along the microtubules leading to the pole and a fraction of 
ASPM was found at the minus ends of central spindle microtubules (Figure 1E). 
Throughout telophase and cytokinesis ASPM was predominantly positioned in a 
narrow ring at the centre of the midbody (Figure 1F and see Additional file 4). This 
localisation was most visible when using the C-terminal antibody 279-3.  
 Immunoblot analysis using the 217-2 N-terminal anti-ASPM antibody 
identified a 410kDa ASPM band in each of a panel of human and monkey cell lines 
(Figure 1G). This band corresponds to the expected size of the 3447 amino acid wild-
type ASPM protein. Other investigators have reported that at least three predominant 
ASPM splice variants may exist (8). In accordance with the reported literature, 217-2 
would be predicted to recognise wildtype ASPM and the largest variant V1, however 
we saw no evidence for the existence of V1 in our whole cell extracts. We were 
unable to optimise antibodies 216-1 and 279-3 for Western blotting at endogenous 
levels of ASPM. However, these antibodies recognise recombinant forms of the 
ASPM protein expressed in and purified from bacteria (results not shown). 
  
ASPM distribution is microtubule dependent  
To examine the dependence of ASPM localization upon microtubules, we first treated 
HeLa cells with 5µg/ml of the microtubule depolymerising drug nocodazole for 60 
minutes. Under these conditions γ-tubulin immunostaining was maintained at spindle 
poles but ASPM 216-1 staining was lost, indicating that the mitotic distribution of 
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ASPM is microtubule-dependent (Figure 2A). We next challenged HeLa cells with 
10µM taxol for 60 minutes, a treatment that induces the formation of multiple 
microtubule asters in mitotic cells. ASPM 216-1 immunostaining was observed at the 
centre of these asters (Figure 2B), suggesting a specific localization to microtubule 
minus ends. ASPM was not specifically associated with the anastral γ-tubulin foci 
also seen in taxol-treated cells (Figure 2C). 
 
SiRNA mediated ASPM knockdown leads to repositioning of the mitotic spindle 
and cytokinesis dysfunction. 
To determine the effects of loss of ASPM function upon cell cycle progression we 
carried out ASPM RNA interference experiments. As a normal human NPC culture 
amenable to RNAi studies was not available we chose to perform these tests in the 
extensively characterised and readily transfectable U2OS osteosarcoma cell line using 
two individual ASPM siRNAs (ASP1 and ASP2) and a luciferase (GL3) control. A 
clear reduction in ASPM at the spindle poles of dividing cells was detected after 
transfection with ASP1 and ASP2 for 72 or 96 hours. By 72 hours post transfection 
with ASP1, ASPM (detected with the anti-ASPM 216-1 antibody at the spindle poles 
of mitotic cells was detectable in only 24% (6/25) of metaphase cells and completely 
knocked down in 76% of dividing cells, whereas ASP2 siRNA achieved a partial 
knockdown in 92% (23/25) metaphase cells (Figure 3A) and complete knock down in 
8% of dividing cells. Comparative immunofluorescence analysis of average integral 
intensity measurements of immunofluorescently labelled centrosomal ASPM was 
performed for twenty-five metaphase U2OS cells treated with either ASP1, ASP2 or 
GL3 siRNAs. In comparison to the average ASPM spindle pole signal measured in 
the GL3 treated metaphases, a significant decrease of 84.3% in the average integral 
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intensity of ASPM signal at the spindle pole was calculated after 72hr treatment with 
ASP1, and 55.2% after treatment with ASP2 (Table 1). Immunofluorescence and 
Western blotting could not detect a change in overall expression level of ASPM in 
interphase cells (Figure 3B, 3C), suggesting that ASPM is stabilised when associated 
with the nuclear matrix and is more open to degradation after nuclear envelope 
breakdown. We therefore chose to investigate the phenotype associated with knock 
down of ASPM at the spindle poles of dividing cells.  
A substantial reduction in proliferation of U2OS cells was observed after 
siRNA treatment in a Celltitre Blue cell viability assay (Figure 3D). Assessment of 
the proportions of 2N:4N DNA content by flow cytometry 48 hours and 72 hours after 
ASPM siRNA treatment distinguished 4N cells in G2/M from tetraploid cells that had 
failed cytokinesis by confirming the presence or absence of Cyclin B1. We identified 
an increase in the proportion of 2N cells in G1, a reduction of cells in G2/M and an 
increase in tetraploid cells in ASPM siRNA treated cells (Figure 3E). These data are 
consistent with both a decrease in the number of cells undergoing mitosis and a failure 
of cytokinesis. This observation was corroborated by microscopic examination of 
immunofluorescently labelled cells after 48 and 72 hours of ASP1 and ASP2 siRNA 
knockdown, which indicated a decrease in mitotic index and an increase in 
multinucleate cells and large mononucleate cells with multiple centrosomes consistent 
with a failure to complete cytokinesis (Figure 3F). The number of cells in cytokinesis, 
defined in this instance as daughter cells linked by narrow cytoplasmic bridges 
containing midbodies, was also decreased by ASPM siRNA. 
To gain further insight into the ASPM knockdown phenotype, we carried out 
phase contrast time-lapse imaging of living U2OS cells 72 hours post-ASP1or GL3 
siRNA treatment. The results of four independent experiments were combined to 
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produce the final data set. We monitored 126 cell divisions of GL3 treated U2OS cells 
and 94 cell divisions following ASP1 siRNA. Depletion of ASPM had a profound 
effect on U2OS cell division. Three major phenotypic anomalies were identified; an 
increase in the proportion of divisions with the mitotic spindle perpendicular to the 
plate surface, an increase in cytokinesis failure, and an increase in apoptosis.  
Normal symmetrical division necessitates positioning of the mitotic spindle 
parallel to the surface of the imaging dish resulting in cleavage plane orientation 
perpendicular to the dish (Figure 4A, see Additional file 5). In 37% of ASP1 siRNA 
knockdowns (n=36) random deviation in the position of the mitotic spindle was 
observed (Table 2) with a significant increase in spindle positioning approximately 
perpendicular to the surface of the dish (Figure 4A, see Additional file 6). This 
spindle alignment is reminiscent of that observed in asymmetric divisions in mouse 
progenitor cells of the neuroepithelium (35). We therefore termed these divisions 
asymmetric. In comparison, only 10.3% (n=13) of GL3 treated cells exhibited such 
asymmetric divisions.  
A second consequence of ASPM depletion observed by time-lapse imaging 
was cytokinesis failure (Table 2), leading to the formation of multinucleated cells. 
Although we observed this phenomenon in a minor population of ASP1 siRNA-
treated cells that underwent symmetrical division (6.4%, n=6), the phenotype was far 
more prevalent in ASP1 treated cells that had undergone asymmetric divisions 
(28.7%, n=27) (Figure 4A, see Additional file 6). In contrast, cytokinesis failure was 
observed in only 3.2% (n=4) of symmetric cell divisions and 4% (n=5) of asymmetric 
cell divisions in GL3 treated cells. In this culture system asymmetric cell division 
initially results in one daughter cell anchored to the culture dish with the second 
daughter cell positioned above the first (i.e., being extruded towards the observer see 
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Additional file 6) and not attached to the substrate. We observed that in many 
instances the second daughter cell was able to subsequently make contact with the 
dish and successful cytokinesis occurred. Only 38% (5 of 13 cells) of asymmetrical 
divisions in GL3 control experiments failed cytokinesis compared with 75% (27 of 36 
cells) of asymmetrical ASP1 treated cells. Therefore asymmetrical division per se 
does not fully account for increased cytokinesis failure in ASP1 siRNA treated U2OS 
cells.                                                                                     
Thirdly, a visible increase in cell death was observed in cells transfected with 
ASP1, 72 hours post transfection. Apoptosis was observed in mononucleate cells, 
binucleate cells (Figure 4A, see Additional file 7) and in cells exiting mitosis but 
exhibiting cytokinesis failure. To quantitate the extent of ASP1 siRNA induced 
apoptosis we performed an in situ activated caspase-3 assay on unfixed U2OS cells 
after 96 hours of siRNA treatment (Figure 4B). On average, ASP1 siRNA treated 
cells demonstrated a 2.7 fold increase in caspase-3 positive apoptotic cells compared 
to control GL3 siRNA cells (mean percentage of apoptotic GL3 siRNA cells in a total 
cell population= 7% (s.d.=3.3%) compared to mean percentage of apoptotic ASP1 
siRNA cells=18.7% (s.d.=6%) (Figure 4C). 
It has previously been reported that ASPM is required for precise orientation 
of the mitotic spindle in specialised mouse NPC (35). Our data demonstrates that 
ASPM function is a determinant of spindle position and division symmetry even in 
non-neuronal derived cells, suggesting that complete absence of ASPM function 
during human development might be expected to affect whole body development. 
Since this is not the observed phenotype in MCPH, the effect of ASPM mutation on 
the function of the ASPM protein expressed in MCPH patients was a logical 
progression of our studies. 
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An ASPM C-terminal splice donor site mutation induces novel splicing and 
reduces mitotic spindle pole association  
ASPM contains a number of potential functional domains. Following the positional 
cloning of the ASPM gene, the initial genotype-phenotype correlation studies in 
MCPH patients did not reveal a clustered distribution of microcephaly-associated 
mutations in ASPM (5, 15) and there were therefore few clues to which of these 
domains were most important for ASPM function.  
We have previously characterized a C-terminal ASPM mutation as a 
homozygous intronic mutation at IVS25 +1G>T (9984 +1 G>T), identified in 
individuals of a consanguineous family of Northern Pakistani origin (15). This 
mutation lies downstream of the Armadillo repeat-like domain (Figure 5A). Splice 
site prediction programs forecast the outcome of this mutation to be the removal of 
the intron 25 splice donor site, resulting in translational extension of exon 25 by 29 
amino acids before the incorporation of a stop signal. We predicted this would result 
in either the synthesis of a truncated ASPM protein of 395kDa (3357 amino acids) 
that would not include the anti-ASPM 279-3 peptide sequence, or that it could lead to 
ASPM depletion due to mRNA degradation via the NMD pathway.  
To determine the effect of the IVS25+1G>T mutation on ASPM mitotic 
expression and localisation, comparative immunofluorescence microscopy of dividing 
ASPMwt and ASPM IVS25 +1G>T fibroblasts was performed using our N-terminal 216-1 
anti-ASPM antibody. Quantitative analysis of spindle pole staining revealed a 
significant reduction in ASPM levels at the PCM in ASPM IVS25 +1G>T fibroblasts 
(Figure 5B, C) (n=80, average integral intensity ASPMwt=16427.01 µm2 (s.e.m. = 
1166.3 µm2), average integral intensity ASPMIVS25 +1G>T=2325.1 µm2 (s.e.m. = 260.1 
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µm
2), p=<0.0001; Average area ASPMwt= 4.80µm2(s.e.m. = 0.27µm2), average area 
ASPMIVS25 +1G>T t= 1.28µm2 (s.e.m = 0.08µm2), p=<0.0001). Unexpectedly, analysis 
of ASPM IVS25 +1G>T fibroblasts immunofluorescently labelled with the C-terminal 
anti-ASPM 279-3 antibody also revealed weak but clearly visible spindle pole 
staining (Figure 5B), suggesting the IVS25+1G>T mutation did not induce a protein 
truncation.  
To investigate the effect of the IVS25+1 G>T ASPM mutation on the ASPM 
protein, we carried out immunoblotting of cell lysates from control (ASPMwt) and 
patient (ASPM IVS25 +1G>T) fibroblasts with the 217-2 N-terminal anti-ASPM antibody. 
Expression of full length ASPM (410kDa) in ASPMwt cell lines was observed and a 
band of approximately similar size and equivalent intensity was detected in ASPM 
IVS25 +1G>T
 protein extracts (Figure 5D). Thus the IVS25 +1 G>T mutation does not 
instigate NMD or protein instability in fibroblasts. Due to the large size of both the 
full length ASPM and the predicted IVS25+1G>T truncated product (395kDa) we 
were unable to directly determine size differences in the proteins by immunoblotting. 
To further explore the effect of the IVS+1G>T mutation, RT-PCR of ASPM 
exons 24-28 of ASPMwt and ASPM IVS25 +1G>T fibroblast mRNA was performed and 
the single PCR product obtained from each was sequenced. Wildtype ASPM sequence 
was observed in the ASPMwt fibroblast mRNA. As expected the G>T mutation at the 
exon 25 splice donor site invalidated the native splice site sequence in the ASPM IVS25 
+1G>T
 mRNA. However, transcription did not continue for the expected 29 amino 
acids before the incorporation of a STOP codon. Unexpectedly, an in-frame cryptic 
splice donor site nine base pairs upstream was recognised and utilised (Figure 5E, F). 
The use of the upstream cryptic splice donor site would result in the production of an 
ASPM protein from which only a tripeptide motif (amino acids 3326-3328) is deleted 
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(Figure 5E). Our immunofluorescence data therefore indicates that the loss of three 
amino acids in the C-terminus of ASPM is apparently sufficient to drastically reduce 
the ability of the protein to localise with the microtubules at the PCM at the spindle 
poles. The fact that fibroblasts from this MCPH patient have a significant decrease in 
the quantity of microtubule associated ASPM suggests the presence of a functional C-
terminal domain in ASPM that is critical for normal ASPM function. 
 
Expression of C-terminal fragments of ASPM inhibits spindle assembly and 
induces mitotic delay in HeLa cells  
Our immunostaining data in patient cells indicates a function mediated by the extreme 
C-terminal region of ASPM is required for its localization to spindle poles. We 
therefore examined the consequences for mitotic cells of expressing C-terminal 
fragments of ASPM upon mitotic progression. Plasmids directing the expression of 
GFP fused to three different fragments of 301 (D1), 222 (D2) and 163 (D3) amino-
acids from the C-terminal sequence of ASPM were created (Figure 6A) to determine 
whether ectopic expression of these fragments would disrupt the function of 
endogenous ASPM in a dominant-negative manner. 
 HeLa cells were transfected with the plasmids and observed 24 hours post 
transfection. Each construct led to similar abnormalities that included the generation 
of a large number of cells with morphological features consistent with an early mitotic 
arrest (Figure 6B, panels a-c) and in many cells membrane blebbing was also evident 
(Figure 6B, panels b-c). The DNA within these cells was highly condensed and 
occasionally fragmented, while spindle microtubule organisation was severely 
disrupted. Where visible, microtubule focusing and spindle formation appeared to be 
fundamentally impaired (Figure 6B, panel a, arrowheads). In most cells the density of 
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microtubules was decreased (Figure 6B, panel b, arrowheads). γ-tubulin 
immunostaining invariably revealed the presence of two separate foci in these cells 
(Figure 6B, panel c, arrows), consistent with the hypothesis that these were cells 
displaying a disrupted mitosis. Endogenous ASPM immunoreactivity was dispersed 
(not shown). This is consistent with the observation of diminished microtubule 
density and our earlier finding that the ASPM spindle pole association is microtubule-
dependent. It is also consistent with the interpretation that expression of these ASPM 
fragments directly inhibited the localisation of endogenous ASPM to spindle poles. Of 
control cells expressing GFP alone, 3% (n=245) displayed an apoptotic or mitotic 
delay phenotype, in comparison with 33% (n=135) of cells expressing ASPM-D1-
GFP; 26% (n=127) of cells expressing ASPM-D2-GFP; and 17% (n=131) of cells 
expressing ASPM-D3-GFP. Similar observations were obtained in transfected COS-7 
cells (not shown). We conclude that a high proportion of HeLa cells expressing 
ASPM C-terminal fragments, particularly those containing the whole of the armadillo 
repeat-like region (D1 and D2), are defective in assembling a functional spindle. This 
leads to mitotic arrest and eventual apoptosis. 
 
Expression of ASPM COOH-terminal GFP-fusion proteins induces cytokinesis 
failure in COS-7 and HeLa cells 
In addition to the severe mitotic defects seen in COS-7 and HeLa cells transfected 
with C-terminal fragments of ASPM, we also observed a subset of cells that appeared 
to have undergone mitosis but had failed to complete cytokinesis (Figure 6B, panels 
d-f). Defects ranged from cells containing large, highly lobular nuclei and peripheral 
microtubule bundles (Figure 6B, panel d, arrows) to cells containing discrete nuclei 
separated by aberrant microtubule arrays (Figure 6B, panel e, arrow), or structures 
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resembling residual central spindles (Figure 6B, panel f, arrow). In neither case was 
there clear evidence for the presence of a cleavage furrow.  
 To exclude fixation artefacts we used co-expression of a GFP-tagged 
microtubule plus-end binding protein, EB3 (39,40) as a means of observing 
centrosomes and the tips of growing microtubules and midbody structures in living 
COS-7 cells. Expression of low levels of EB3-GFP alone had no significant impact on 
cell division in transfected COS-7 cells (J. M. Askham, unpublished data, 41). The 
phenotypes of COS-7 cells co-expressing ASPM-D2-GFP and EB3-GFP confirmed 
our immunostaining observations (Figure 6C). Expression of ASPM-D2-GFP alone 
led to the formation of binucleated cells (Figure 6C panel a). Co-expression of EB3-
GFP revealed that these cells contained central spindle structures or loose parallel 
microtubule arrays (Figure 6C, panel b-d). In some examples centrosomes were seen 
in close association with well-separated nuclei (Figure 6C, panel d), indicating that 
the primary defect in these cells was a failure in cytokinesis after the completion of 
chromosomal segregation. The observations from both fixed and living COS-7 cells 
were therefore consistent with a role for ASPM in organizing the central spindle 
microtubule array in mitotic cells from anaphase onwards.  
Conclusions  
Our study provides a mechanism by which mutations in the human ASPM gene could 
result in a developmental reduction of brain size, and supports the hypothesis that the 
MCPH phenotype arises due to defective NPC division. By examining the 
consequences of siRNA mediated knockdown of spindle pole associated ASPM 
expression and the phenotypes seen following expression of fusion proteins derived 
from the ASPM C-terminus we have identified critical roles for human ASPM in 
spindle microtubule organisation, spindle positioning and in the regulation of 
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cytokinesis even in a non-neural cell type. Similar phenotypes have been previously 
reported in Drosophila asp mutants (25,28-33). We suggest that ASPM is a 
reasonably stable protein and that nuclear matrix associated ASPM is less open to 
degradation than ASPM after nuclear envelope breakdown. ASPM was recently 
confirmed as a gene involved in the regulation of mitosis in human cells as part of the 
substantive MitoCheck integrated research project (42, www.mitocheck.org). As an 
element of this high-throughput whole genome RNAi screen, automated live cell 
image analysis of ASPM knockdown identified similar phenotypes to those identified 
in our study. Although mitotic spindle position was not a phenotype for which 
analytical parameters were specifically established, other mitotic phenotypes that 
could lead to a decrease in cell division were identified. Metaphase delay was robustly 
observed with further phenotypes of mitotic delay, problems with metaphase 
alignment, cell death and poly-lobed nuclei identified with one of two siRNAs 
utilised.  
We have previously shown that Aspm is preferentially expressed during 
cerebral cortical neurogenesis in the mouse brain (5). The time of maximal Aspm 
expression in the neuroepithelium corresponds to the period of proliferative cell 
division, and the subsequent down-regulation of Aspm expression is concomitant with 
a switch to asymmetrical cell division (35). We have now demonstrated that inhibition 
of ASPM function by siRNA causes a highly penetrant loss of precision in the 
placement of the mitotic spindle in dividing U2OS cells, resulting in an alteration of 
division mode from the symmetrical to the asymmetrical plane. This implies that in 
U2OS cells symmetrical cell division in a plane that is perpendicular to the substrate 
is an active process that requires functional ASPM, rather than a simple default 
pathway. Our data therefore demonstrates that the requirement for ASPM in the 
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maintenance of symmetrical divisions is not limited to specialised NPCs as previously 
assumed, but that it plays a general role in mitotic cells.  
A logical consequence of this hypothesis is that the normal development of the 
whole human body should be affected by ASPM loss of function. Indeed in 
Drosophila loss of asp function results in larval lethality (25, 28-33). Paradoxically 
however, the only known phenotype in individuals with homozygous mutations in 
ASPM is MCPH (5,15). Mutations in ASPM are scattered throughout the gene, yet 
they result in a single clinical MCPH phenotype. Our immunoblot data of ASPM 
expression in fibroblast lysates from an MCPH patient carrying the IVS25+1G>T 
homozygous mutation established that the MCPH phenotype in this patient did not 
result from complete ASPM loss and confirmed a previous report that ASPM mutation 
does not instigate the NMD pathway (8). Partly functional ASPM proteins may 
therefore be expressed in the cells of MCPH individuals, and we hypothesised that 
ASPM mutations caused protein truncations and that the MCPH phenotype resulted 
from the common loss of a C-terminal functional domain that led to partial loss of 
ASPM function. Surprisingly, our data from patient cells demonstrates that the MCPH 
phenotype can arise from a cryptic splicing event that removes only nine nucleotides 
of intragenic sequence within the C-terminal region of ASPM and results in a 
reduction in ASPM localisation to the spindle poles. The minimal IVS25+1G>T 
mutation therefore causes a decrease in the efficiency of ASPM spindle pole 
localisation without an associated decrease in overall ASPM protein levels or a major 
increase in gross mitotic abnormalities in patient fibroblasts. We propose that 
expression of this subtly impaired mutant ASPM protein is sufficient to induce small 
deviations in the precision of mitotic spindle positioning in symmetrically dividing 
cells.  This contrasts with the severe mitotic phenotypes seen in cultured cells 
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following more profound disruption of ASPM function by siRNA knockdown of 
ASPM spindle pole expression, or expression of dominant negative ASPM C-terminal 
domains. 
The existence of individuals homozygous for mutations in ASPM who exhibit 
a small brain but who are otherwise grossly normal leads us to infer that either (a) a 
functional compensatory mechanism exists in somatic cells or (b) neurogenic cell 
divisions are sufficiently different to the majority of somatic cell divisions to be 
profoundly and differentially affected by a subtle perturbation of ASPM function. The 
reason for this may lie in the unique morphology of the cells undergoing division in 
the neuroepithelium during cortical expansion (35). In vertebrates, apical NPC are 
apicobasally elongated to a remarkable extent and possess a small apical surface. To 
execute accurate symmetrical divisions in such cells would require extremely precise 
cleavage along the apicobasal axis (43). Small deviations in spindle position leading 
to cleavage plane reorientation would result in a transition from symmetrical to 
asymmetrical division. In the majority of somatic cells such deviations could be 
tolerated due to their relatively large apical and basal surfaces. However in NPC such 
deviation may be sufficient to drive a decrease in the number of cells successfully 
completing symmetrical cell division. This would impair the expansion of the 
progenitor pool that normally occurs at early stages of cortical development. As a 
consequence, the NPC pool would be insufficient to produce the number of neurones 
required for a normal sized brain.  
What then is the function of ASPM during the later stages of mitosis? We 
observed an ASPM localisation at the minus ends of central spindle microtubules 
during anaphase and at the centre of the midbody during telophase and cytokinesis. 
Microtubules of the mitotic apparatus are a critical contributor to cleavage furrow 
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positioning. Both astral microtubules and overlapping equatorial MTs in the central 
spindle have been implicated as playing a significant role in this process (44-47). We 
therefore see a number of possibilities for ASPM function during cytokinesis. ASPM 
might directly contribute to the organisation of midzone microtubules with the 
cytokinesis defects seen after ASPM functional inhibition arising secondary to central 
spindle disorganisation. Alternatively, its presence at the centrosome might influence 
the function of astral microtubules. It also seems possible that ASPM might 
participate more directly in the coupling of spindle microtubule function to cortical 
events during furrowing. For example, ASPM might be able to influence the local 
activity of myosins through its interactions with EF-hand Ca2+ binding factors such 
as calmodulin, or to influence signalling events during cytokinesis through 
interactions with binding partners such as citron kinase (38). 
In conclusion, a major finding of our study is that ASPM plays a role in cell 
division, not just those in NPCs, but in other cell types. We propose that MCPH5 
patients have enough residual ASPM activity to successfully complete functionally 
symmetrical cell divisions in all tissues except the developing brain, where extremely 
unusual morphological constraints result in a specific defect in cortical neurogenic 
mitosis in response to imprecise spindle position. In this we echo the arguments 
presented by Fish et al., in an authoritative commentary on NPC division (43). We 
have also identified a three amino acid sequence in the C-terminal domain of ASPM 
in an MCPH patient reduces localisation of ASPM to the PCM implying that this 
region of ASPM mediates an important function in NPCs. Future studies will be 
aimed at defining whether this region of ASPM mediates an important interaction 
with a novel binding partner. 
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Methods 
Cell culture 
HeLa and COS-7 cells were obtained from the European Collection of Cell Cultures. 
U2OS human osteosarcoma cells and SH-SY5Y neuroblastoma cells were obtained 
from the ATCC Cell Biology Collection (ATCC-LGC Promochem Partnership, South 
London, UK). Human neonatal dermal fibroblasts (ASPM wt) were obtained from 
Genlantis (San Diego, California). Each cell line was maintained in accordance to 
manufacturer’s guidelines. 
 The MCPH5 patient fibroblast cell culture (ASPMIVS25+1G>T) was created from 
a forearm skin biopsy. The collection of biopsy sample was approved by the Ethical 
Committee of Leeds (East) Research Ethics Committee (REC reference number 
05/Q1206/80) and informed consent was collected from the subject and parents. The 
skin biopsy was finely cut and homogenised to desegregate the cells prior to plating in 
Hams F10 medium containing L-glutamine and 25mM HEPES (Invitrogen, Paisley, 
U.K.), 20% fetal calf serum (Invitrogen) and 1% penicillin/streptomycin (Invitrogen) 
and incubated in 5% CO2 at 37oC 
 
Antibodies and Cytotoxic reagents 
Rabbit polyclonal antibodies against peptide sequences corresponding to aa363-386 
(sequence code 216-1; KDNYGLNQDLESES), aa426-441 (sequence code 217-2; 
PEDWRKSEVSPRIPEC) and aa3443-3458 (sequence code 279-3; 
SRLKPDWVLRRDNMEE) of the human ASPM sequence were raised by Affiniti 
Research Products Limited, Exeter, UK. BLAST analysis revealed no significant 
homology to other published sequences. Antibody specificity in immunostaining was 
demonstrated by peptide pre-competition of immune serum and lack of specific 
staining from pre-immune serum (not shown). A rat anti α-tubulin antibody was 
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obtained from Serotec Ltd, Oxford, UK. A mouse monoclonal antibody specific for γ-
tubulin was obtained from the Sigma-Aldrich Company, Dorset, UK. Mouse 
monoclonal and rabbit polyclonal anti-GFP antibodies were obtained from Clontech 
(Saint-Germain-en-Laye, France). Secondary antibodies were Molecular Probes 
highly cross-absorbed rabbit, mouse or rat IgG-specific Alexa conjugates (Cambridge 
BioScience, Cambridge, UK). DAPI, nocodazole and taxol were obtained from the 
Sigma-Aldrich Company. 
 
Immunofluorescence  
Cells were cultured on glass coverslips. Transfections of GFP-constructs were 
performed using GeneJuice (Novagen) according to the manufacturer’s instructions 
and coverslips were processed for immunocytochemistry 24 hours after transfection. 
Cells were fixed for 5 minutes in ice-cold methanol and labelled as previously 
described (48). Immunofluorescence analysis was performed using a Leica TCS-SP 
confocal microscope as described previously (49) and a Zeiss Axiovert 200 inverted 
microscope coupled to an Orca II ER CCD camera controlled by AQM6 software 
(Kinetic Imaging, Wirral, UK) as described previously (50). All confocal images 
presented here are maximum intensity projections. Figures were assembled and 
annotated using Adobe Photoshop CS2. 
 
Immunoblotting 
To perform immunoblotting of ASPM, cells were lysed in standard RIPA buffer, 
protein concentration determined and PAGE carried out using 3-8% Tris Acetate 
precast gradient gels (Invitrogen) in a Surelock electrophoresis tank (Invitrogen) on 
25µg protein. Subsequent protein transfer onto PVDF membrane (Invitrogen) was 
performed in the same system in accordance with the manufacturer’s instructions.  
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siRNA knockdown of ASPM expression 
Double-stranded RNA oligos that target ASPM mRNA were obtained from 
Dharmacon Inc Lafayette, CO, USA. siRNA ASPM1 targets sequence 
UGCCAUGGUGCAACUUGCU(nt 691-709) (synthetic oligos 
UGCCAUGGUGCAACUUGCUUU and AGCAAGUUGCACCAUGGCAUU) and 
siRNA ASPM2 targets GUGGUGAAGGUGACCUUUC (nt 2804-2822) (synthetic 
oligos GUGGUGAAGGUGACCUUUCUU and 
GAAAGGUCACCUUCACCACUU). A GL3 siRNA targeting the firefly luciferase 
sequence CUUACGCUGAGUACUUCGA was used as a control (51).  
5x105 U2OS cells per well of a six well plate containing a coverslip or 4x105 
U2OS cells per 35mm plate for live cell imaging experiments were transfected 16 
hours post plating with siRNA using Oligofectamine transfection reagent (Invitrogen). 
siRNA transfection mix was prepared for each plate as follows; 12µl of 20µM siRNA 
was added to 200µl Optimem serum free medium (Invitrogen). 8µl of Oligofectamine 
was added to 52µl Optimem medium in a separate tube and incubated at room 
temperature for 10 minutes. The diluted transfection reagent was added to the tube 
containing the diluted siRNA and incubated for a further 20 minutes. 128µl of 
Optimem was then added to give a final siRNA transfection mix volume of 0.4 ml. 
The growth medium was removed from the cells which were washed once with 
growth medium without serum or antibiotics. 0.6ml growth medium without serum or 
antibiotics was added to the plate, followed by the 0.4 ml transfection mix. The 
transfection was incubated at 37oC for 4 hours before adding 1ml growth medium 
containing 20% FCS and antibiotics. The cells were incubated for a total of 48 or 72 
hours before analysis. 
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FACS analysis of DNA content 
48 and 72 hours after siRNA treatment U2OS cells were released by trypsin digestion, 
pelleted, washed in PBS and resuspended in 1 ml of cold 70% ethanol then stored at –
20oC. Prior to Flow Cytometric analysis the cells were washed in block buffer (PBS 
containing 1% BSA), permeabilised for 15 minutes in block buffer containing 0.25% 
Triton X-100 and then incubated for 1 hour in 100µl of mouse anti cyclin B1 (BD-
Pharmingen 554177 diluted 1:500). Cells were washed in block buffer then incubated 
for 1 hour with Alexa Fluor 488 anti-mouse IgG (Molecular probes A-11029, diluted 
1:300). Cells were finally washed and then incubated at 37oC for 30 min in 0.5 ml 
PBS containing 3µl of 6mg/ml RNAse and 12.5 µl of 5mg/ml propidium iodide. 
10,000 single cell events per sample were analysed for DNA and cyclin B1 content to 
identify G1 (2N DNA content, low cyclin B1), G2/M (4N DNA content, high cyclin 
B1) and tetraploid cells (4N DNA content, low cyclin B1) using a Facscalibur 
Facscan (Becton Dickinson). 
 
CaspGLOWTM Fluorescein Active Caspase-3 Assay 
U2OS cells were treated with GL3 or ASP1 siRNA duplex for 96 hours prior to 
commencing Caspase-3 analysis. Detached and adherent cells were collected and 
washed with PBS. The CaspGLOWTM Fluorescein Active Caspase-3 assay (Medical 
and Biological Laboratories Ltd, Woburn, MA, USA) was performed on 3x105 GL3 
and ASP1 treated cells as per manufacturer’s protocol. The cells were then 
resuspended in PBS containing 50ug/ml propidium iodide, 100ug/ml RNAse A and 
0.1% (v/v) Triton X-100 and incubated at 37oC for one hour. Active caspase-3 was 
detected by flow cytometry using a BD LSRII (Becton Dickinson) capturing 10000 
events per sample. Three independent experiments were performed  
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Time-lapse live cell imaging 
Phase contrast time-lapse imaging experiments of live cells were performed on a 
Zeiss Axiovert 200M inverted microscope incorporating an automated motorised 
stage, contained within a Perspex incubation chamber heated to a constant 37oC 
temperature (Solent Scientific, UK). Cells were cultured, transfected and imaged in 
35mm glass-bottomed culture dishes (Iwaki brand; Asahi Techno Glass Corporation, 
Japan, obtained from Barloworld Scientific, UK). Growth media was replaced with 
2ml media supplemented with 20mM HEPES. Cells were observed under oil with an 
x40 Plan Neofluar 1.3 aperture objective. Images were captured with a Hamamatsu 
Orca Camera, using Volocity 3 acquisition software (Improvision, Coventry, UK) 
over a period of 4 hours. Multiple positions were imaged at a rate of one image per 
minute.  Live cell fluorescence imaging experiments were performed on a Zeiss 
Axiovert 200 inverted microscope contained within a Perspex incubation chamber 
heated to a constant 37oC temperature (Solent Scientific, UK). Imaging was 
performed as described previously (50). Figures were assembled and annotated using 
Adobe Photoshop CS2. 
 
Celltitre Blue cell viability assay and assessment of mitotic abnormalities in 
fixed immunolabelled siRNA treated cells.  
To perform cell viability assays on siRNA treated cells, U2OS cells were plated in 96-
well plates at 103 cells per well and grown at 37oC for 16 hours before siRNA 
treatment (as above). Wells were washed once with serum free medium and then 60µl 
serum free medium and 40 µl siRNA transfection mix were added. The transfection 
was completed as described above. 72 hours after siRNA transfection, Celltitre Blue 
reagent (Promega) was added to wells following manufacturer’s instructions. The 
plate was incubated at 37oC for a further 8 hours and the conversion of resazurin to 
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fluorescent resorufin, an assay of metabolic rate, was determined using fluorimetry 
(560nm excitation wavelength, 615nm emission wavelength). In parallel experiments 
siRNA treated and control cell cultures were co-immunostained using combinations 
of antibodies that included α-tubulin, γ-tubulin and ASPM. DNA was counterstained 
using DAPI. At least 1000 total cells per sample were then assessed by direct 
microscopic observation to determine mitotic index, the number of cells in 
cytokinesis, and the proportion of cells with abnormal numbers of nuclei and 
centrosomes. 
 
Comparative analysis of ASPM spindle pole expression in ASPMwt, ASPM IVS25 
+1G>T
 cell lines and GL3, ASP1 and ASP2 treated U2OS cells 
To compare relative quantities of ASPM at the spindle poles of ASPMwt and ASPM 
IVS25 +1G>T cells, cells were simultaneously immunofluorescently labelled using 216-1 
anti-ASPM antibody. Images were captured on an Olympus BX61 upright microscope 
using x100 oil UPlanFLN 1.30 aperture objective, F-View II monochromatic camera 
(Olympus Soft Imaging Solutions Ltd, Helperby, North Yorkshire, U.K.) and CellP 
Software (Olympus Soft Imaging Solutions Ltd), with a 1 second exposure time, 
ensuring the signal intensities visualised in the images were directly comparable. 
ASPM PCM signal intensity was measured as integral intensity (defined as the sum of 
all the intensities of a region of interest multiplied by the pixel area). To compare the 
integral integrity values of ASPM localised at the spindle pole in ASPMwt and 
ASPMIVS25 +1G>T cells a paired two tailed Student t-test was used. A P-value of less 
than 0.0001 was considered highly statistically significant.  
To compare the integral integrity values of ASPM localised at the spindle pole 
in GL3, ASP1 and ASP2 treated metaphase U2OS cells captured with a 2 second 
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exposure time, a Mann Whitney test was used. A P-value of less than 0.005 was 
considered statistically significant.  
  
RNA preparation, reverse transcription and sequencing 
RNA was obtained from ASPMwt and ASPMIVS25 +1G>T fibroblasts using Trizol 
extraction as per manufacturers instructions. cDNA was produced using Superscript 
reverse transcriptase (Stratagene Agilent Technologies, West Lothian, UK) as per 
manufacturers direction with oligo dT primers (Promega). ASPM exons 25-28 were 
amplified using forward (TCCGAAGTTGTAATCGCAGT) and reverse 
(CTTGCAGGGGATTTGTGATT) primers. 
 
Plasmid construction 
The plasmids pASPM-D1-GFP, pASPM-D2-GFP and pASPM-D3-GFP were 
constructed by cloning nt 9530-10434 (aa3177-3477), 9766-10434 (aa3256–3477) 
and 9943-10434 (aa3315–3477) of ASPM respectively in frame into the BamHI and 
XhoI restriction sites in the GFP expression plasmid pJMA2-eGFP (49). All 
constructs were fully sequenced before use. The construction and characterization of 
an EB3-GFP expression plasmid will be described elsewhere (J. M. Askham, 
manuscript in preparation).  
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Abbreviations 
ASPM  Abnormal spindle-like microcephaly associated  
CDK5RAP2 CDK5 regulatory subunit-associated protein 2 
CENPJ Centromeric protein J 
DCNT1 Dynactin1 
FACS  Fluorescence-activated cell sorter 
GFP  Green fluorescent protein 
MCPH  Autosomal recessive primary microcephaly 
NPC  Neural progenitor cell 
NMD  Nonsense mediated decay 
nt  Nucleotide 
PBS  Phosphate buffered saline 
s.d.  Standard deviation 
s.e.m.  Standard error of the mean 
siRNA  Small interfering RNA 
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Figures 
 
Figure 1 - Organisation of the ASPM protein and its cellular distribution during 
mitosis. 
A. Structure of the 3477 amino acid human ASPM protein. The region corresponding 
to the microtubule-binding domain of Drosophila Asp (24) is shown in white.  The 
calponin homology domains (aa920-1261) are in light grey; ASNP repeats are dark 
grey boxes (aa316-342, 366-400); 81 IQ domains (aa1267-3225) are shown as vertical 
stripes; the armadillo repeat-like domain (aa3294-3327) is a black box; and the C-
terminal region is depicted by diagonal stripes.  The location of potential nuclear 
localization sequences are indicated by asterisks and the location of the peptides used 
to raise polyclonal antibodies, by dashed arrows. B-F. Analysis of ASPM distribution 
following immunostaining. HeLa cells were fixed and stained with antibodies specific 
for ASPM (green), anti-α-tubulin (red) and with DAPI (blue) to identify nuclei. 
Panels B-E utilised Anti-ASPM 216-1, whilst anti-ASPM 279-3 was used in panel F.  
B. ASPM is predominantly nuclear in interphase cells. Scale bar=10µm. C. ASPM is 
localised to the spindle poles during metaphase. Scale bar=5µm. D. A globular 
distribution of ASPM (green) is seen around the γ-tubulin (red) immunopositive core 
of metaphase HeLa cell spindle poles. DNA (DAPI staining) is shown in blue 
(confocal image). Scale bar=2.5µm. E. Single 0.5µm confocal section through the 
centre of a telophase HeLa cell immunostained to reveal ASPM (green) and α-tubulin 
(red). In addition to broad spindle pole-associated labelling (arrowhead), ASPM also 
localizes to the minus ends of central spindle microtubules (arrow). Scale bar=2.5µm. 
F. A late telophase fibroblast immunostained with anti-ASPM 279-3 (green), anti-α-
tubulin (red) and with DAPI (blue). ASPM is predominantly localized at the midzone 
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of the central spindle. Scale bar =10µm. G. Immunoblotting of cell lysates of COS7 
cells (lane 1), U2OS cells (lane 2), primary fibroblasts (lane 3) and HeLa cells (lane 
4) with anti-ASPM 217-2 antibody. This identifies a protein of approximately 410kDa 
in each lane. A blot stained with anti-β-actin is shown as loading control. 
 
Figure 2 - The ASPM spindle association is microtubule-dependent 
A. Panel showing a nocodazole-treated mitotic HeLa cell immunostained for ASPM 
216-1 (green), γ-tubulin (red) and DAPI (blue). ASPM is not clustered around the γ-
tubulin of the spindle poles in the absence of microtubules. Scale bar=5µm. B. Panel 
showing a taxol-treated mitotic HeLa cell immunostained for ASPM 216-1 (green), 
α-tubulin (red) and DAPI (blue). ASPM concentrates in the centre of taxol-induced 
microtubule asters (arrows). Scale bar=5µm. C. Panel showing a taxol-treated mitotic 
HeLa cell immunostained for ASPM 216-1 (green), γ-tubulin (red) and DAPI (blue). 
ASPM (arrowhead) does not specifically co-localize with γ-tubulin foci (arrow) in 
taxol-treated cells. Scale bar=5µm.  
 
Figure 3 - Phenotypic traits of siRNA mediated depletion of ASPM in U2OS 
cells. 
A. Reduction in spindle pole associated ASPM (using the anti-ASPM 216-1 
antibody), 72hrs post transfection with ASP1 and ASP2 siRNAs relative to GL3 
control dsRNA Scale bar = 10µm.  B. ASPM (216-1 antibody) expression in 
interphase cells 72hrs post GL3, ASP1 and ASP2 transfection. Scale Bar = 10µm. C.  
Western Blot using rabbit polyclonal anti-ASPM 217-2 antibody, showing ASPM 
expression in lysates from GL3, ASP1 and ASP2 treated U2OS cells. A β-actin 
loading control is shown. 25µg protein for each sample was loaded. D. Celltitre Blue 
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cell viability assay was carried out 72 hours post siRNA treatment, showing a 
reduction in cell viability in ASP1 and ASP2 siRNA transfected cell cultures. E. Flow 
cytometric analysis of DNA content and cyclin B1 status 48 and 72 hours post ASPM 
siRNA treatment, demonstrating a decrease in the number of cells in G2/M and an 
increase in the number of tetraploid G1 cells. F. Analysis of immunofluorescently 
labelled cells treated for 48 and 72h with ASP1 and ASP2 siRNAs. A decrease in 
mitotic index and an increase in the number of multinucleate cells and cells with 
centrosome numbers greater than 2 are seen following ASPM knockdown. A decrease 
in the number of cells displaying morphological hallmarks of cytokinesis, such as the 
presence of a midbody, is also seen. These observations are consistent with a failure 
to complete cytokinesis. 
 
Figure 4 - siRNA mediated ASPM induces misorientation of the plane of cell 
division, cytokinesis failure and increased apoptosis in U2OS cells  
A. Panels showing phase contrast images of living U2OS cells taken from time-lapse 
movies. Time points are shown in the bottom left hand corner of each image. Top 
row. Normal symmetrical division of a GL3 siRNA treated control cell with the 
cleavage plane oriented perpendicular to the cell substrate (see Additional file 5). 
Scale bar =10µm. Middle row. ASP1 siRNA treated cell undergoing an asymmetric 
division with the mitotic spindle positioned perpendicular to the cell substrate. This 
division led to cytokinesis failure with the formation of a binucleate cell. Arrowhead 
shows the upper daughter cell moving out of the focal plane towards the observer as 
the cleavage furrow is formed parallel to the surface of the imaging dish. An arrow 
indicates the lower daughter cell still attached to the surface of the dish (see 
Additional file 6). Scale bar =10µm. Bottom row. Binucleated ASP1 siRNA treated 
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cell undergoing apoptosis (see Additional file 7). Scale bar =10µm. B. Flow 
cytometric analysis of caspase-3 assayed 96 hours after ASP1 and GL3 siRNA 
treatment. An increase in the population of apoptotic (dead) cells is observed in ASP1 
siRNA experiments. C. Histogram showing the mean percentage of apoptotic cells in 
ASP1 and GL3 siRNA caspase-3 assays. A 2.7 fold increase in the percentage of 
apoptotic cells in the ASP1 siRNA population was identified compared to the GL3 
siRNA population. Standard deviation values for the mean are shown as vertical bars. 
 
Figure 5 - ASPMIVS25+1G>T mutation produces a novel splice variant with 
decreased efficiency for spindle pole localisation. 
A. Schematic of the ASPM protein showing the location of the ASPMIVS25+1G>T splice 
site mutation (filled arrows with an upper diamond).  Domains of the protein are 
indicated as described in the legend to Figure 1. Location of epitopes of anti-ASPM 
antibodies are shown beneath the protein. B. Fibroblasts at metaphase immunostained 
using 216-1 anti-ASPM antibody (N-terminal) and the 279-3 anti-ASPM antibody, 
raised against a C-terminal peptide sequence. Note the reduced ASPM localization at 
the mitotic spindle poles of ASPMIVS25+1G>T cells. Scale bar =10µm. C. Chart 
representing integral intensity of ASPM 216-1 antibody staining at the spindle poles 
of ASPMwt and ASPMIVS25+1G>T fibroblast cells. Horizontal lines indicate the average 
integral intensity of the immunostaining. Standard error bars are present. 
ASPMIVS25+1G>T was at statistically significantly lower level (asterisks) at the spindle 
poles than ASPMwt when compared using a paired two tailed t-test. P =<0000.1. D. 
Immunoblotting of fibroblast control (WT) and ASPMIVS25+1G>T (Patient) lysates with 
217-2 anti-ASPM antibody and anti β-actin. Equivalent levels of stable ASPM protein 
are expressed by each cell culture, indicating the IVS25+1G>T mutation does not 
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induce nonsense mediated decay.  E. Sequence analysis of exon 25-exon 26 control 
ASPMwt and Patient ASPMIVS25+1G>T cDNA. The point of removal of the nine 
nucleotides due to the IVS25+1G>T mutation is indicated by an asterisk.  
F. IVS25+1G>T mutation removes the exon 25 splice donor site and instigates the 
utilisation of an in frame splice donor site nine nucleotides downstream. The resultant 
ASPMIVS25+1G>T protein is lacking just three amino acids (3326-3328). 
 
Figure 6 - Mitotic defects in transfected HeLa and COS-7 cells expressing C-
terminal ASPM GFP fusion proteins 
A. Organisation of the 3477 amino acid human ASPM protein as described in the 
legend to Figure 1. C-terminal fragments expressed as fusion proteins with GFP are 
indicated D1- D3. Position of the C-terminal mutation (IVS25+1G>T) is indicated by 
an arrow. B. Panels a, b; HeLa cells expressing ASPM-D1-GFP immunostained to 
reveal GFP (green), α-tubulin (red) and DAPI (blue) then examined by confocal 
microscopy. Aggregates of fusion protein are indicated by arrows. Microtubules are 
disorganized and unfocused (arrowheads) and spindle poles cannot be identified. 
Scale bars=5µm. Panel c; HeLa cells expressing ASPM-D1-GFP immunostained to 
reveal GFP (green), γ-tubulin (red) and DAPI (blue). These abnormal cells possessed 
two spindle poles (arrows) and condensed DNA, suggesting mitotic arrest. Scale 
bar=10µm. Panels d-f; COS-7 cells expressing ASPM-D1-GFP immunostained to 
reveal GFP (green), α-tubulin (red) and DAPI (blue). Transfected cells were large and 
binucleate (panels e-f) or possessed abnormal lobular nuclei (panel d). Peripheral 
microtubule arrays or bundles were present (panels d-e, arrows). Panel f shows a 
binucleate cell containing a midbody (arrow). Scale bar=20µm. C. Aberrant 
cytokinesis in living COS-7 cells expressing ASPM-D2-GFP. Panel a; a binucleate 
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COS-7 cell expressing ASPM-D2-GFP. Small aggregates of fusion protein can be 
seen. Panels b-d; COS-7 cells co-expressing ASPM-D2-GFP and EB3-GFP, used as a 
marker of microtubule organisation. Binucleate cells containing EB3-GFP positive 
midbodies (panels b and c, white arrows) or no midbody and a loose microtubule 
array (panel d, black arrow) are shown. Black arrow in panel c indicates the position 
of an incomplete and unusually asymmetrical cleavage furrow. White arrows in panel 
d indicate the position of centrosomes associated with the two nuclei, suggesting 
chromosomal segregation has occurred but cytokinesis has failed. In all panels 
asterisks indicate the location of nuclear structures. Images are shown in inverted 
grayscale for clarity. Scale bar=10µm. 
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Tables 
 
Table 1 Down regulation of ASPM in response to siRNA mediated ASPM 
depletion in metaphase U2OS cells. 
 
GL3 ASP1 ASP2 
Average integral intensity (µm2) 14805 2318 6631 
Knockdown of spindle  
pole expression (%) 0 84.3 55.2 
p value  <0.001 0.005 
 
Comparative immunofluorescence analysis, measured as average integral intensity, 
was performed on the immunofluorescent centrosomal ASPM signal of twenty-five 
metaphase U2OS cells treated with ASP1, ASP2 or GL3 siRNAs. In comparison to 
the average integral intensity of ASPM spindle pole signal measured in the GL3 
treated metaphases, a significant decrease in the average integral intensity of ASPM 
signal at the spindle pole was calculated after 72hr treatment with ASP1, and with 
ASP2. The knock down is expressed as a percentage of the expression in GL3 cells. 
In each case t-tests showed the levels of knockdown to be significant. 
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Table 2 Effect of siRNA mediated ASPM depletion on spindle pole position and 
cytokinesis. 
 Total number  Symmetric division  Symmetric division Asymmetric division Asymmetric division 
 of divisions  with cytokinesis with cytokinesis with cytokinesis with cytokinesis 
  (% of total)  failure (% of total) (% of total) failure (% of total) 
      
GL3 126 109 (86.5%) 4 (3.2%) 8 (6.3%) 5 (4.0%) 
      
ASP1 94 52 (55.3%) 6 (6.4%) 9 (9.6%) 27 (28.7%) 
      
 
 
Time-lapse imaging of living U2OS cells was performed 72 hours post-GL3 and 
ASP1 siRNA treatment. The results of four independent experiments were combined 
to produce the final data set. Depletion of ASPM had a profound effect on U2OS cell 
division, resulting in an increase in the proportion of divisions with the spindle 
positioned perpendicular to the plate surface (asymmetrical division) and an increase 
in cytokinesis failure.  
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Additional files 
Additional file 1 
(Higgins 2010 Human ASPM participates Additional file 1.pdf) 
 A comparison of ASPM interphase localisation in HDF cells using ASPM N- 
and C-terminal ASPM antibodies   
Cells were fixed and stained with the N-terminal ASPM antibody 216-1or 217-2 or 
the C-terminal antibody 279-3 (green), anti-α-tubulin (red) and DAPI (blue) to 
identify nuclei. Scale bar=10µm.  
 
Additional file 2  
(Higgins 2010 Human ASPM participates Additional file 2.pdf) 
A comparison of ASPM metaphase localisation in HDF cells using ASPM N- 
and C-terminal ASPM antibodies   
Cells were fixed and stained with the N-terminal ASPM antibody 216-1or 217-2 or 
the C-terminal antibody 279-3 (green), anti-α-tubulin (red) and DAPI (blue) to 
identify nuclei. Scale bar=10µm.  
 
Additional file 3 
(Higgins 2010 Human ASPM participates Additional file 3.pdf) 
ASPM is localised at the spindle poles in metaphase cells for a range of cell 
types  
HeLa, COS-7, U2OS, SH-SY5Y and HDF cells were fixed and stained with the N-
terminal ASPM antibody 216-1 (green), anti-α-tubulin (red) and DAPI (blue) to 
identify nuclei. Scale bar=10µm.  
 
Additional file 4 
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(Higgins 2010 Human ASPM participates Additional file 4.pdf)   
ASPM is positioned in a narrow ring at the centre of the midbody during 
telophase in a range of cell types 
 Cells were fixed and stained with the N-terminal ASPM antibody 279-3 (green), anti-
α-tubulin (red) and DAPI (blue) to identify nuclei. Scale bar=10µm. 
 
Additional file 5 
(Higgins 2010 Human ASPM participates Additional file 5.mov) 
Symmetrical division in GL3 luciferase control siRNA treated cells. 
A U2OS cell treated with GL3 siRNA undergoing symmetrical division with the 
mitotic spindle parallel to the surface of the imaging dish. This division results in two 
daughter cells and complete cytokinesis. 
 
Additional file 6  
(Higgins 2010 Human ASPM participates Additional file 6.mov) 
Asymmetrical division and cytokinesis failure in a siRNA mediated ASPM 
depleted U2OS cell. 
A U2OS cell treated with ASP1 siRNA undergoing an asymmetric division with the 
mitotic spindle perpendicular to the surface of the imaging dish. This results in one 
daughter being extruded vertically from the dividing cell, towards the observer, while 
the other remains attached to the substrate. In this example cytokinesis fails, resulting 
in the formation of a binucleate cell.  
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Additional file 7 
(Higgins 2010 Human ASPM participates Additional file 7.mov) 
ASPM depleted binucleate U2OS cell undergoing apoptosis. 
This movie shows a binucleate U2OS cell following treatment with ASP1 siRNA, 
undergoing apoptosis. 
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